Literature DB >> 18156376

Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.

C Calvo-González1, J Reche-Frutos, J Donate-López, J García-Feijoó, M Leila, C Fernández-Pérez, J Garcia-Sánchez.   

Abstract

AIMS: This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.
RESULTS: Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 microm to 2065.7 microm at the 24-week follow-up.
CONCLUSION: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18156376     DOI: 10.1136/bjo.2007.128942

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  3 in total

Review 1.  The treatment of wet age-related macular degeneration.

Authors:  Antonia M Joussen; Norbert Bornfeld
Journal:  Dtsch Arztebl Int       Date:  2009-05-01       Impact factor: 5.594

Review 2.  Current status of anti-vascular endothelial growth factor therapy in Europe.

Authors:  Sebastian Wolf
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

Review 3.  Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases.

Authors:  Rajib Kumar Dutta; Srinivasan Chinnapaiyan; Hoshang Unwalla
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-18       Impact factor: 8.886

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.